A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro

Osteoblast Differentiation ◽

Kinase Inhibitor ◽

CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo

Microvascular Research ◽

10.1016/j.mvr.2021.104146 ◽

2021 ◽

Vol 136 ◽

pp. 104146

Author(s):

Handong Dan ◽

Xinlan Lei ◽

Xin Huang ◽

Ning Ma ◽

Yiqiao Xing ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.142 ◽

2015 ◽

Vol 137 ◽

pp. 61

Author(s):

C.L. Schwab ◽

D.P. English ◽

J.D. Black ◽

S. Lopez ◽

S. Bellone ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Erbb Receptor ◽

Erbb Receptor Tyrosine Kinase

The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma

Oncotarget ◽

10.18632/oncotarget.2648 ◽

2014 ◽

Vol 5 (24) ◽

pp. 12753-12768 ◽

Cited By ~ 30

Author(s):

Emmy D.G. Fleuren ◽

Melissa H.S. Hillebrandt-Roeffen ◽

Uta E. Flucke ◽

D. Maroeska W.M. te Loo ◽

Otto C. Boerman ◽

...

Keyword(s):

Tyrosine Kinase ◽

Ewing Sarcoma ◽

Kinase Inhibitor ◽

Vitro Activity ◽

In Vitro Activity ◽

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

Tumor Biology ◽

10.1007/s13277-015-3218-4 ◽

2015 ◽

Vol 36 (7) ◽

pp. 5505-5513 ◽

Cited By ~ 3

Author(s):

Liancheng Zhu ◽

Salvatore Lopez ◽

Stefania Bellone ◽

Jonathan Black ◽

Emiliano Cocco ◽

...

Keyword(s):

Endometrial Cancer ◽

Tyrosine Kinase ◽

Second Generation ◽

Kinase Inhibitor ◽

Erbb Receptor ◽

Erbb Receptor Tyrosine Kinase

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro

Pharmaceutics ◽

10.3390/pharmaceutics6040632 ◽

2014 ◽

Vol 6 (4) ◽

pp. 632-650 ◽

Cited By ~ 12

Author(s):

Johanna Weiss ◽

Dirk Theile ◽

Zdenek Dvorak ◽

Walter Haefeli

Keyword(s):

Tyrosine Kinase ◽

Interaction Potential ◽

Kinase Inhibitor ◽

Drug Transporters ◽

Drug Metabolising Enzymes

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

10.32388/jfobd7 ◽

2020 ◽

Author(s):

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth

Delayed Therapy with Receptor Tyrosine Kinase Inhibitor Nintedanib Diminished Chronic Rejection in a Murine Lung Transplant Model

10.1055/s-0041-1725623 ◽

2021 ◽

Author(s):

J. Mauer ◽

A. Kuckhahn ◽

J. Distler ◽

B. Spriewald ◽

M. Ramsperger-Gleixner ◽

...

Keyword(s):

Tyrosine Kinase ◽

Chronic Rejection ◽

Lung Transplant ◽

Kinase Inhibitor ◽

Murine Lung ◽

Transplant Model

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Glomerular Changes in Rats Administered ABT-869, a Multitargeted Receptor Tyrosine Kinase Inhibitor - Linking Ultrastructure to Mechanism

Microscopy and Microanalysis ◽

10.1017/s1431927609097566 ◽

2009 ◽

Vol 15 (S2) ◽

pp. 16-17

Author(s):

J Fagerland ◽

S Morgan

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Extended abstract of a paper presented at Microscopy and Microanalysis 2009 in Richmond, Virginia, USA, July 26 – July 30, 2009

The effect of combination treatment with gemcitabine and the EGFR-receptor tyrosine kinase inhibitor iressa with photodynamic therapy in bladder cancer

European Urology Supplements ◽

10.1016/s1569-9056(03)80175-6 ◽

2003 ◽

Vol 2 (1) ◽

pp. 44

Author(s):

C.H. Briggs ◽

C.D. Betts ◽

K.J. O'Flynn ◽

J.V. Moore ◽

N.W. Clarke

Keyword(s):

Bladder Cancer ◽

Photodynamic Therapy ◽

Tyrosine Kinase ◽

Combination Treatment ◽

Kinase Inhibitor ◽